PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 30, 2021Seminars in Arthritis and Rheumatism149 citationsOpen Access

The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems

View Full Paper
TKTore K KvienKPKashyap PatelVSVibeke Strand

Key Points

Key points are not available for this paper at this time.

Abstract

Greater utilization of biosimilars in the US is an achievable goal but the federal government, pharmaceutical companies, and medical associations/institutions will need to work together to address patient and physician concerns and to remove incentives for using more expensive treatment options.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kvien et al. (2021) studied this question.

synapsesocial.com/papers/69d87582d2f7327e70ae336bhttps://doi.org/10.1016/j.semarthrit.2021.11.009
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Developing the Nation's Biosimilars Program2011 · 197 citations
  2. 2Oxford Textbook of Rheumatoid Arthritis2020 · 6 citations
  3. 3Delivering affordable cancer care in high-income countries2011 · 718 citations
  4. 41989 American Association for Cancer Research1989 · 297 citations
  5. 5To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry2018 · 156 citations